{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:21Z","timestamp":1761986541659,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00c3\u00b4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014255","name":"Fonds de dotation CSL Behring pour la recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014255","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clim.2020.108419","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T02:28:02Z","timestamp":1586572082000},"page":"108419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study"],"prefix":"10.1016","volume":"215","author":[{"given":"Paul","family":"Legendre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doumit","family":"Chahwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zora","family":"Marjanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marguerite","family":"Vignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Morelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Darrodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Emmanuel","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Ouzegdouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Chaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Montestruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurore","family":"Caumont-Prim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lisande","family":"Le Jouan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Godeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2020.108419_bb0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0002-9343(84)90320-6","article-title":"Intravenous immune globulin therapy in hypogammaglobulinemia. a review","volume":"76","author":"Pirofsky","year":"1984","journal-title":"Am. J. Med."},{"issue":"146","key":"10.1016\/j.clim.2020.108419_bb0010","first-page":"335","article-title":"High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia","volume":"1960","author":"Liese","year":"1992","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.clim.2020.108419_bb0015","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors","volume":"73","author":"Griffiths","year":"1989","journal-title":"Blood."},{"key":"10.1016\/j.clim.2020.108419_bb0020","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica."},{"key":"10.1016\/j.clim.2020.108419_bb0025","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.clim.2020.108419_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(95)90346-1","article-title":"Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs","volume":"345","author":"Gardulf","year":"1995","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.clim.2020.108419_bb0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108419_bb0040","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0140-6736(95)90367-4","article-title":"Subcutaneous gammaglobulin for patients with secondary hypogammaglobulinaemia","volume":"345","author":"Hammarstr\u00f6m","year":"1995","journal-title":"Lancet Lond. Engl."},{"volume":"10","year":"2019","series-title":"Guideline on the Clinical Investigation of Human Normal Immunoglobulin for Subcutaneous and\/or Intramuscular Administration (SCIg\/IMIg)","key":"10.1016\/j.clim.2020.108419_bb0045"},{"volume":"12","year":"2019","series-title":"Guideline on core SmPC for Human Normal Immunoglobulin for Intravenous Administration (IVIg)","key":"10.1016\/j.clim.2020.108419_bb0050"},{"key":"10.1016\/j.clim.2020.108419_bb0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ejh.12900","article-title":"Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: long-term data of the SIGNS study","volume":"99","author":"Reiser","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.clim.2020.108419_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13078","article-title":"A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency","author":"Benbrahim","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.clim.2020.108419_bb0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ejim.2014.09.009","article-title":"Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia","volume":"25","author":"Blot","year":"2014","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.clim.2020.108419_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100324","article-title":"Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement","volume":"9","author":"Duraisingham","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clim.2020.108419_bb0080","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.leukres.2015.10.013","article-title":"Risk of secondary hypogammaglobulinaemia after rituximab and Fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study","volume":"39","author":"De Angelis","year":"2015","journal-title":"Leuk. Res."},{"volume":"16","year":"2020","series-title":"Guideline on core SmPC for Human Normal Immunoglobulin for Intravenous Administration (IVIg)","key":"10.1016\/j.clim.2020.108419_bb0085"},{"volume":"6","year":"2020","series-title":"Hi\u00e9rarchisation des Indications des Immunoglobulines Humaines Polyvalentes","key":"10.1016\/j.clim.2020.108419_bb0090"},{"key":"10.1016\/j.clim.2020.108419_bb0095","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Infectious diseases Society of America, clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.clim.2020.108419_bb0100","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","article-title":"Prophylactic immunoglobulin therapy in secondary immune deficiency \u2013 an expert opinion","volume":"12","author":"Agostini","year":"2016","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108419_bb0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clim.2020.108419_bb0110","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica."},{"key":"10.1016\/j.clim.2020.108419_bb0115","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.jaci.2013.01.036","article-title":"Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement","volume":"131","author":"Agarwal","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108419_bb0120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1348-0421.12060","article-title":"Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections","volume":"57","author":"G\u00fcnther","year":"2013","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.clim.2020.108419_bb0125","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/00365548.2013.769279","article-title":"Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia","volume":"45","author":"Svensson","year":"2013","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.clim.2020.108419_bb0135","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7861\/clinmedicine.18-5-364","article-title":"Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases","volume":"18","author":"Shillitoe","year":"2018","journal-title":"Clin. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661619306564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661619306564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:00:18Z","timestamp":1761494418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661619306564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":25,"alternative-id":["S1521661619306564"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108419","relation":{},"ISSN":["1521-6616"],"issn-type":[{"type":"print","value":"1521-6616"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108419"}}